Company intelligence / Profile preview

Amlogenyx

Novato, California, United States

Ownership: Private
Development stage: Other

Overview

Amlogenyx is advancing a novel AAV9-based gene therapy to deliver cathepsin A (PPCA) enzyme to the brain, which has shown substantial reduction of amyloid beta (Aβ42) accumulation in preclinical murine models, exceeding results of monoclonal antibody therapies targeting the same pathology. No clinical data are yet available.[1][2][3]

Therapeutic areas: Neurology
Modalities: Gene therapyBiologic
Industry: Biotech

Drug pipeline

1 asset

AM805

Preclinical

Partnerships

St. Jude Children's Research Hospital (scientific/technology origins)Ultragenyx (manufacturing and IP platform)

Beyond the preview

Go deeper on Amlogenyx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amlogenyx.

Explore the full profile